ABMD Posts Stellar Results, HNSN Rallies, STJ Gets FDA Nod, Watch Out For VBLT

(RTTNews) - Shares of ABIOMED Inc. (ABMD) rose more than 27 per cent in extended trading on Tuesday, following stellar Q3 fiscal 2015 results - with profit and revenue well above analysts' expectations.

In other news, the company's Impella RP (Right Percutaneous) System has received FDA approval under a Humanitarian Device Exemption. This innovative medical device is the first percutaneous single access heart pump designed for right heart support to receive FDA approval, according to the company.

ABMD closed Tuesday's trading at $38.63, down 2.38%. In after-hours, the stock was up 27.13% at $49.11.

Apricus Biosciences Inc.'s (APRI) product candidate for the treatment of Raynaud's phenomenon - RayVa - has been issued a patent by the United States Patent and Trademark Office.

The patent is expected to expire no earlier than its twenty-year term in 2032.

RayVa is currently under a phase 2a clinical trial in patients with Raynaud's phenomenon.

APRI closed Tuesday's trading at $1.22, up 0.41%. In after-hours, the stock was up 1.64% at $1.24.

Can-Fite BioPharma Ltd.'s (CANF) drug candidate CF602 has demonstrated efficacy in treatment of sexual dysfunction in preclinical studies, showing 118% improvement in erectile function measures as compared to placebo.

The company has plans to initiate a pre-clinical development program for CF602 in order to file an investigational new drug application with the FDA to allow human phase I studies for the indication of sexual dysfunction.

CANF closed Tuesday's trading at $3.38, up 3.68%. In after-hours, the stock was up 2.66% at $3.47.

Hansen Medical Inc. (HNSN) has completed the first clinical procedure with the Magellan Robotic System in Australia - performing transarterial chemoembolization, or TACE in short.

TACE is a minimally-invasive procedure involving targeted intravascular delivery of chemotherapeutic agents directly to a tumour in the liver.

Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedure types in centres across the U.S. and Europe, according to the company.

HNSN closed Tuesday's trading 11.30% higher at $0.64. In after-hours, the stock was up 16.88% at $0.74.

St. Jude Medical Inc.'s (STJ) FlexAbility Ablation Catheter, a new ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias, has been approved by the FDA.

The FDA approval of the FlexAbility catheter, which received CE Mark in Europe last year, further strengthens St. Jude Medical's fast-growing ablation technology portfolio and expands the ability of physicians to treat patients battling abnormal heart rhythms, noted the company.

STJ closed Tuesday's trading at $66.03, up 0.97%.

VBL Therapeutics (VBLT) has begun to catch the eye of the investment community as can be seen from the new highs recorded by the stock.

The company is scheduled to report top line results from two phase II studies of its drug candidate VB-201 for the treatment of psoriasis and ulcerative colitis in the first quarter of 2015.

VBLT closed Tuesday's trading 11.70% higher at $16.23.